Interactions between ovine lentiviral vectors and primary cells
Rebecca McLean Moredun Research Institute
MRP Inter-Institutional Post-Graduate Competition 28th/29th June 2016
www.moredun.org.uk
• Many infectious diseases of livestock do not yet have an effective vaccine
• Viral vectors
• Lentiviral vaccine vectors
– Ovine lentivirus
Livestock vaccines
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
BFV PFV
SFV-3
WEHV-1
WEHV-2
WDSV
GALV MMLV
FeLV RSV
FIV
BLV
ENTV-2
HTLV-1
HTLV-2
HIV-1
SIVmac
EIAV
VMV
MPMV
MMTV HERV-K
spumaretrovirus
deltaretrovirus lentivirus
betaretrovirus gammaretrovirus
epsilonretrovirus
alpharetrovirus
ENTV-1 JSRV
BIV
Retroviruses
Ovine lentivirus
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Lentivirus Structure
Matrix Capsid Nucleo- capsid
Gag
Protease
Pro Surface Unit
Trans Membrane
Env
Reverse Transcriptase
RnaseH Integrase
Pol
R U5 U3 R U5 U3
Ψ
LTR LTR
Env SU
TM
Gag
CA
MA
NC
Pol IN
PR
RT
Pro
Vif Tat
Rev
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Why lentiviruses?
• Can infect non-dividing antigen presenting cells (APCs)
• Long lasting, stable transgene expression
• Produce cellular immune responses1
• Infectious disease
• Generate neutralising antibodies2
1) Rowe et al. 2006. Mol Ther. 13. 2) Iglesias et al. 2006. J Gene Med. 8.
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Lentivirus Replication Cycle • Easily manipulate genome
How will it work?
Nucleus
Cytoplasm
Lentiviral vaccine vector • Self-inactivating • Integration deficient
Antigen presentation
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Aims
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
1. Construct and evaluate modified ovine lentiviral vaccine vectors
2. Study the innate immune response to ovine lentiviral vectors in primary ruminant dendritic cells and
macrophages cultured in vitro
Basic characterisation
Enhance safety profile
Improve production efficiency
Efficiency of infection
Immune responses
Interactions with primary cells
Vector Production
Harvest lentiviral vector
48 hours later...
Transfect human fetal kidney cell line
Infect target cells (CRFK)
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Self-Inactivating
Matrix Capsid Nucleo- capsid
Gag
Protease
Pro Surface Unit
Trans Membrane
Reverse Transcriptase
RnaseH Integrase
Pol
R U5 U3 R U5 U3
Ψ
3’ LTR 5’ LTR
Recombination events
LTR LTR eGFP
LTR LTR eGFP Promoter
LTR LTR eGFP
11.32%
13.65%
0.28%
eGFP SSC
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Integration Deficient
Matrix Capsid Nucleo- capsid
Gag
Protease
Pro Surface Unit
Trans Membrane
Env
Reverse Transcriptase
RnaseH Integrase
Pol
R U5 U3 R U5 U3
Ψ
LTR LTR
5751 GAGGGGAATA GATCATTGGC AAGTGGccTA CACTCATTTT GAAGATAAGA R G I D H W Q V D Y T H F E D K I 5801 TATTACTAGT ATGGGTAGAA ACAAATTCGG GATTAATTTA TGCAGAAAGG L L V W V E T N S G L I Y A E R 5851 GTGAAAGGGG AGACAGGACA AGAATTTAGA GTAACAGCTA TGAAGTGGTA V K G E T G Q E F R V T A M K W Y 5901 TGCTCTGTTT GCCCCAAAAT CATTGCAATC TGATAATGGG CCAGCATTTG A L F A P K S L Q S D N G P A F V 5951 TAGCAGAAGC AACACAACTG CTAATGAAAT ATTTAGGGAT AATACATACA A E A T Q L L M K Y L G I I H T 6001 ACAGGGATAC CTTGGAATCC ACAGTCTCAA GCTCTAGTGG ccAGGGCTCA T G I P W N P Q S Q A L V E R A H
D,D-35-E motif
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Non-integrated DNA outcome
1-LTR episome 2-LTR episome
Provirus
Pre-Integration Complex
• Intact viral coding region
• Transgene expression
• Lack origin of replication (ORI)
U3 U5 R
U3 U5 R U3 U5 R
U3 U5 R U3 U5 R
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Transgene
Transgene
Transgene
∆IN Vector - Results
• Dividing and non-dividing CRFK • Arrested using aphidicolin
• High multiplicity of infection (MOI=1)
• eGFP-positive cells measured every 2 days for 12 days 48 hours – 50% of cells released from cell cycle arrest
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
0
10
20
30
40
50
60
70
80
90
100
2 4 6 8 10 12
eG
FP P
osi
tive
Ce
lls
(% o
f d
ay 2
)
Time Post-Infection (Hours)
Parent Vector (Dividing Cells)
Parent Vector (Non-Dividing Cells)
ΔIN (Dividing Cells)
ΔIN (Non-Dividing Cells)
Improved Safety
• Self-inactivating (SIN)
• Integration deficient (∆IN)
• Combined and used to infect CRFK
• Flow analysis at 72 hours post infection
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
1.00E+00
1.00E+01
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
Parent SIN+ΔIN
Vir
al T
itre
(IU
/ml)
Vector Construct
Virus Construct
Type Viral Titre
(IU/ml)
Reduction in titre compared
to Parent
HIV-1 Parent 6.2x109
270-fold1 SIN+ΔIN 2.3x107
EIAV Parent 9.3x108
290-fold1 SIN+ΔIN 3.2x106
VMV Parent 2.6x106
5-fold SIN+ΔIN 5.7x105
1) Ellis et al. 2012. Molecular Therapy–Nucleic Acids . 1.
107
106
105
104
103
102
101
100
Primary Cells
• Ovine peripheral blood
• CD14+ → IL-4 & GM-CSF
• Monocyte derived dendritic cells (DCs)
• Day 6: infect
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Day 6 Day 9 Day 0 10x 20x 20x
HIV and VMV Vector comparisons
• HIV-1 derived lentiviral vectors commonly used
• MOI=1
• Analysed level of eGFP positive cells over time
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 6 8 10 12
eG
FP P
osi
tive
Ce
lls (
%)
Time Point (hours)
VMV Vector HIV Vector SIN-∆IN VMV Vector
High level of cell death
• Flow cytometry analysis
– 72 hours
– Only lifted off cells expressing eGFP
– Large percentage (>90%) of the cells expressing eGFP were dead.
Infected Cells 72 hours post-infection
• Mechanism of cell death
• Initial time points – 12 hours and 24 hours
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
56.50% 0.68%
14.51%
Annexin V
PI
Necrotic Late Apoptotic
Early Apoptotic
12 hours post-infection
Apoptosis
• Time course
• Naturally low levels of apoptosis in all controls
• Infected cells undergo apoptosis due to infection after 4 hours.
0
5
10
15
20
25
30
35
40
45
50
1 2 3 4 6 8 10 12
Earl
y A
po
pto
tic
Ce
lls (
%)
Time Point (hours)
Infected Heat Inactivated Control Uninfected Untreated
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
What’s inducing cell death?
DNA?
Vector which is unable to reverse transcribe the RNA does not induce apoptosis
YMDD AAAA
Sensing of DNA induces apoptosis
05
1015202530354045
1 2 3 4 6 8 10 12
Earl
y A
po
pto
tic
Ce
lls (
%)
Time Point (hours) Infected Untreated ∆RT Vector
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Next Stages
• Some adjuvants induce apoptosis1
• Phagocytosis
• Cross presentation
Increasing safety profile Primary Cells Background
Primary cell population Apoptotic bodies
Secondary cell population
Cross presentation
1) Kool et al., 2008. J Immunology. 181.
Interactions with APCs Conclusions
Next Stages
Increasing safety profile Primary Cells Background
32.67%
18.67%
47.81%
PKH-67 (green)
PK
H-2
6
(red
)
Interactions with APCs Conclusions
+6 hours
+4 hours
Outputs
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
• Cloned in a range of pathogen genes:
• Chlamydia abortus
• Teladorsagia circumcincta
• Louping Ill Virus
• Toxoplasma gondii
• Improve vaccine efficiency
Conclusions
• Ovine lentiviral vectors are promising candidates for gene delivery in ruminants.
• Integrase deficient and self-inactivating.
• Primary cells can efficiently be infected in vitro.
• Infected cells undergo apoptosis after 4 hours of infection.
• Similar to action of some adjuvants.
• Apoptotic bodies can be phagocytosed.
Increasing safety profile Primary Cells Interactions with APCs Background Conclusions
Acknowledgements
Funders
Moredun Scientific Scottish Government
Moredun Research Institute
David Griffiths Gary Entrican
Ann Wood Sean Wattegedera
Mara Rocchi Maira Connelly Tom McNeilly
David Longbottom Helen Todd
BioServices David Kennedy
Roy Davie Manus Graham
The Roslin Institute
Jayne Hope Hope Lab Group